opportunityknocking, I partly understand your frustrations, but you have to realize that if Dr. Moro had not been both CEO and lead scientist there would have been no more BOCX today. Or should they have survived the hard times they have gone through you would have seen about 3 - 10 the number of shares outstanding today. (could have been more because excessive dilution would scare away investors and attract shorting hedge funds and market makers and then you end up in a deadly spiral with no end in sight, something so often seen in Penny-stock land.
Another thing is that since we operate down here in the "underworld" with no institutional support, you have to rely on finding new investors to support the stock price and you find these by promoting the company through Penny-stock advisers. Sorry to say it but that is the way things work down here.
A kind of mindbogglingly example is that When Lebed promoted the stock for a short period of time in October, November of 2006 we reached a higher peak of 1.07 on heavier volume (2 million shares) than when BOCX signed a license agreement with a 3 billion dollar Diagnostic company (peak of .79 on 619000 shares traded). So go figure!!
Obviously I think BOCX should try, like in 2006 to get some articles published in various newspapers, as it might work relatively well in finding new investors, but we are still stuck here in penny-stockland and while we are here we are much better of keeping cost and dilution as low as possible while we wait for Abbott and IMA to commercialise the technology, so please do not promote BOCX into hiring an expensive CEO at this point in time.
With regard to attending other medical conferences like the one you mentioned, yes that would be OK, but you have to understand that the conference they attend to on an annual basis (ISOBM) have all the largest diagnostic companies in the world attending and believe me that the big boys, who need to know about this technology already knows. Some of these might just have taken the position that should the technology be commercialised by Abbott they will simply engage in a sub-licence agreement with Abbott. So perhaps we are better of if BOCX attends the annual ISOBM conference and spent the rest of the time with research and development and license agreements. This approach will keep both cost and dilution low.
All the thing that BOCX set out to do from the beginning are happening, even though it has taken longer than anticipated!
Most of the action with regard to diagnostics are happening beyond our and BOCX'es control (at Abbotts and IMA)at this point in time.
If the technology is what it promises to be, we WILL prevail and reap very large gains considering we are so undervalued, so my view is that we will explode upwards in price in a few days when Abbott comes clean and says that the commercialisation phase has commenced.
In the mean time all we can do is to just sit tight and wait, because it could happen before you know it!!
News 
Market Data 
Discover 
